Turn Therapeutics Inc. reported financial and operating results for the quarter ended June 30, 2026. The company announced that interim Phase 2 data for its lead candidate GX-03 in atopic dermatitis showed activity across a broader patient population than anticipated, prompting an expansion of Stage 2 enrollment to approximately 120–135 patients with moderate-to-severe lesions but lower overall disease extent. Turn Therapeutics appointed former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical and Regulatory Lead on May 18, 2026. Financially, the company reported a net loss of $5.8 million for the quarter, with cash and cash equivalents totaling $10.3 million as of June 30, 2026, providing operational runway into the third quarter of 2027. The company also plans to expand GX-03 development into hidradenitis suppurativa, targeting first patient dosing in Q2 2027. Turn Therapeutics is a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases.
